COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
Microbiol Spectr
; 12(1): e0328623, 2024 Jan 11.
Article
en En
| MEDLINE
| ID: mdl-38009954
ABSTRACT
IMPORTANCE This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
COVID-19
Límite:
Humans
Idioma:
En
Revista:
Microbiol Spectr
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos